Integration of Fe3O4 with Bi2S3 for Multi-Modality Tumor Theranostics
Integration of Fe3O4 with Bi2S3 for Multi-Modality Tumor Theranostics
复制标题
Fe3O4 与 Bi2S3 的集成用于多模态肿瘤治疗学
DOI：
10.1021/acsami.0c05088
复制
发表时间：
2020-05-20
影响因子：
9.5
通讯作者：
Wang, Shige
中科院分区：
文献类型：
--
作者：
Luo, Keyi;Zhao, Jiulong;Wang, Shige
活性氧（ROS）诱导的化学动力疗法（CDT）与光热疗法（PTT）结合使用具有良好的抗癌效果，具有广阔的应用前景。本文通过在牛血清白蛋白（BSA）的羧基和PDA的氨基之间进行酰胺化，制备了Fe3O4@polydopamine (PDA)@牛血清白蛋白(BSA)-Bi2S3复合物作为治疗剂，将Fe3O4@PDA与BSA-Bi2S3化学连接。在该配方中，Fe3O4 NPs不仅可以作为模拟过氧化物酶触发肿瘤中固有H2O2的芬顿反应，产生高细胞毒性羟基自由基（中心点OH）诱导肿瘤凋亡，还可以作为磁共振成像（MRI）造影剂提供精确的癌症诊断。同时，PDA可以阻止Fe3O4氧化，从而支持肿瘤中长期的Fenton反应和肿瘤凋亡。Bi2S3组件具有优异的光热传导性能和计算机断层扫描（CT）成像能力。此外，PDA和Bi2S3使Fe3O4@PDA@BSA-Bi2S3复合材料具有优异的光热转化能力，可导致肿瘤热疗。所有这些优点都发挥了与肿瘤微环境的协同作用，使Fe3O4@PDA@BSA-Bi2S3 NPs成为MRI/ ct监测增强PTT/CDT协同治疗的有效药物。这项研究的发现将引起人们对未来基于生物相容性纳米材料的癌症治疗策略的新兴趣。
The combination of reactive oxygen species (ROS)induced chemodynamic therapy (CDT) and photothermal therapy (PTT) holds a promising application prospect for their superb anticancer efficiency. Herein, we created a novel Fe3O4@polydopamine (PDA)@bovine serum albumin (BSA)-Bi2S3 composite as a theranostic agent, by chemically linking the Fe3O4@PDA with BSA-Bi2S3 via the amidation between the carboxyl groups of BSA and the amino groups of PDA. In this formulation, the Fe3O4 NPs could not only work as a mimetic peroxidase to trigger Fenton reactions of the innate H2O2 in the tumor and generate highly cytotoxic hydroxyl radicals (center dot OH) to induce tumor apoptosis but also serve as the magnetic resonance imaging (MRI) contrast agent to afford the precise cancer diagnosis. Meanwhile, the PDA could prevent the oxidization of Fe3O4, thus supporting the long-term Fenton reactions and the tumor apoptosis in the tumor. The Bi2S3 component exhibits excellent photothermal transducing performance and computed tomography (CT) imaging capacity. In addition, the PDA and Bi2S3 endow the Fe3O4@PDA@BSA-Bi2S3 composite with an excellent photothermal transforming ability which could lead to tumor hyperthermia. All of these merits play the synergism with the tumor microenvironment and qualify the Fe3O4@PDA@BSA-Bi2S3 NPs for a competent agent in the MRI/CT-monitored enhanced PTT/CDT synergistic therapy. Findings in this research will evoke new interests in future cancer therapeutic strategies based on biocompatible nanomaterials.